Literature DB >> 9885014

Differential urinary gonadotrophin profiles in early pregnancy and early pregnancy loss.

J F O'Connor1, N Ellish, T Kakuma, J Schlatterer, G Kovalevskaya.   

Abstract

Early pregnancy loss (EPL), detected by patterns of human chorionic gonadotrophin (hCG) in urine, is the biomarker employed in investigations of the impact of personal, workplace or environmental reproductive toxins on human fertility. An issue central to these studies is what, in terms of urinary hCG expression, constitutes an EPL. This report describes the urinary molecular forms of hCG expressed in menstrual cycles in which a normal pregnancy was conceived, or an EPL occurred, or no apparent conception occurred. Qualitative and significant quantitative differences in the expression of hCG-associated analytes were found between normal pregnancy cycles and EPL cycles. Discriminant analysis calculation based on mole fractions of the different hCG-associated molecules afforded 91 per cent and 80 per cent correct classification of clinical pregnancy cycles and EPL cycles, respectively. Although hCG-associated molecules unique to either EPL or normal pregnancy were not found, what is thought to be an early form of hCG is expressed both at a high frequency and at a significantly higher concentration in early normal pregnancy when compared with EPL. The relative absence of this molecule very early in pregnancy may signal a pregnancy loss.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885014     DOI: 10.1002/(sici)1097-0223(199812)18:12<1232::aid-pd439>3.0.co;2-z

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  8 in total

1.  Unbalanced human embryos secrete more hyperglycosylated human chorionic gonadotrophin (hCG-H) than balanced ones.

Authors:  Dimitar Parvanov; Dragomira Nikolova; Rumiana Ganeva; Kristina Nikolova; Magdalena Vasileva; Ivaylo Rangelov; Maria Pancheva; Maria Serafimova; Rada Staneva; Savina Hadjidekova; Fabio Scarpellini; Georgi Stamenov
Journal:  J Assist Reprod Genet       Date:  2020-04-22       Impact factor: 3.412

2.  Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG.

Authors:  S Birken; A Krichevsky; J O'Connor; J Schlatterer; L Cole; A Kardana; R Canfield
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

3.  Hyperglycosylated human chorionic gonadotropin as an early predictor of pregnancy outcomes after in vitro fertilization.

Authors:  Sandy Chuan; Michael Homer; Raj Pandian; Deirdre Conway; Gabriel Garzo; Lisa Yeo; H Irene Su
Journal:  Fertil Steril       Date:  2013-12-17       Impact factor: 7.329

Review 4.  Extragonadal actions of chorionic gonadotropin.

Authors:  Prajna Banerjee; Asgerally T Fazleabas
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

Review 5.  New discoveries on the biology and detection of human chorionic gonadotropin.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2009-01-26       Impact factor: 5.211

6.  The sensitivity and specificity of hyperglycosylated hCG (hhCG) levels to reliably diagnose clinical IVF pregnancies at 6 days following embryo transfer.

Authors:  Charles M Strom; Ruben Bonilla-Guererro; Ke Zhang; Kevin J Doody; David Tourgeman; Ruben Alvero; Marcelle I Cedars; Beryl Crossley; Raj Pandian; Rajesh Sharma; Julie Neidich; Denise Salazar
Journal:  J Assist Reprod Genet       Date:  2012-04-24       Impact factor: 3.412

Review 7.  hCG, the wonder of today's science.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2012-03-28       Impact factor: 5.211

Review 8.  hCG: Biological Functions and Clinical Applications.

Authors:  Chinedu Nwabuobi; Sefa Arlier; Frederick Schatz; Ozlem Guzeloglu-Kayisli; Charles Joseph Lockwood; Umit Ali Kayisli
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.